Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 4/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703795 | 1.00 | MAOB (0.40) | MAOBSMPD3DGAT2HIF1APARP1 | |
| SCHEMBL29703828 | 0.90 | SMPD3 (0.41) | SMPD3NPC1 | |
| SCHEMBL23014103 | 0.90 | SMPD3 (0.41) | SMPD3NPC1 | |
| SCHEMBL29939181 | 0.85 | DGAT1 (0.45) | NPC1 | |
| SCHEMBL25150706 | 0.85 | DGAT1 (0.45) | NPC1 | |
| SCHEMBL23013548 | 0.80 | DHODH (0.41) | PARP1 | |
| SCHEMBL29703800 | 0.80 | DHODH (0.41) | PARP1 | |
| SCHEMBL25150620 | 0.79 | MAOB (0.41) | MAOBSMPD3HIF1ASYKMAT2A | |
| SCHEMBL20119340 | 0.78 | SMPD3 (0.51) | SMPD3PARP1SYK | |
| SCHEMBL18817179 | 0.77 | SMPD3 (0.52) | SMPD3PARP1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114555604-A | Pharmaceutical compounds | 瑞威有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | MAOB 873/4885SMPD3 4665/4885DGAT2 4440/4885 |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | GABRA6, CNR1, CHRNA6 | MAOB 1333/4885SMPD3 4677/4885DGAT2 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.